More than 6.5 million Americans are living with heart failure. In the next five years, that number will grow to 8.5 million ...

Chronic heart failure (CHF) is associated with frequent hospitalizations and high mortality. It affects more than 5 million individuals in the USA, and another 660,000 new cases are diagnosed each ...

Inconsistent adherence to the guidelines led to delayed heart failure treatment optimization and underutilization of key ...

Cardiac hypertrophy, characterized by an increase in heart muscle cell size, is often triggered by various stimuli including pressure overload, which can lead to heart failure if left unchecked.

A heart block is a conduction disorder that affects the heart’s electrical system, causing a slower and sometimes irregular ...

Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but there is ...

Researchers have identified the enzyme PKN as a key factor in heart fibrosis, potentially leading to new treatments for heart ...

BACKGROUND: An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms and prognosis. METHODS: Patients with symptomatic HF ...

has been linked to the advancement of heart failure. A group from Nagoya University Graduate School of Medicine in Japan discovered an enzyme called protein kinase N (PKN) that controls cardiac ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and ...